133 related articles for article (PubMed ID: 38584476)
1. Opioid-induced respiratory depression suspected of drug interaction in a prostate cancer patient: a case report.
Hamada H; Suzuki E; Endo M; Mihara Y; Iketani S; Ishida M; Miyasato A; Miyazaki K
Ann Palliat Med; 2024 Mar; 13(2):428-432. PubMed ID: 38584476
[TBL] [Abstract][Full Text] [Related]
2. Drug interactions with aprepitant or fosaprepitant: Review of literature and implications for clinical practice.
Dushenkov A; Kalabalik J; Carbone A; Jungsuwadee P
J Oncol Pharm Pract; 2017 Jun; 23(4):296-308. PubMed ID: 26921085
[TBL] [Abstract][Full Text] [Related]
3. Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers.
Walsh SL; Heilig M; Nuzzo PA; Henderson P; Lofwall MR
Addict Biol; 2013 Mar; 18(2):332-43. PubMed ID: 22260216
[TBL] [Abstract][Full Text] [Related]
4. Simulation of drug-drug interactions between breast cancer chemotherapeutic agents and antiemetic drugs.
Deb S; Hopefl R
Daru; 2023 Dec; 31(2):95-105. PubMed ID: 37223851
[TBL] [Abstract][Full Text] [Related]
5. Aprepitant and fosaprepitant drug interactions: a systematic review.
Patel P; Leeder JS; Piquette-Miller M; Dupuis LL
Br J Clin Pharmacol; 2017 Oct; 83(10):2148-2162. PubMed ID: 28470980
[TBL] [Abstract][Full Text] [Related]
6. Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.
Fujiwara Y; Toyoda M; Chayahara N; Kiyota N; Shimada T; Imamura Y; Mukohara T; Minami H
PLoS One; 2014; 9(8):e104215. PubMed ID: 25121773
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.
Grunberg SM; Dugan M; Muss H; Wood M; Burdette-Radoux S; Weisberg T; Siebel M
Support Care Cancer; 2009 May; 17(5):589-94. PubMed ID: 19037667
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of Dexamethasone when Administered with Fosaprepitant for Chemotherapy-Induced Nausea and Vomiting and Differences in Dose-Dependent Antiemetic Effects.
Shimamoto F; Goto M; Terazawa T; Asaishi K; Miyamoto T; Higuchi K
Asian Pac J Cancer Prev; 2021 Mar; 22(3):871-877. PubMed ID: 33773552
[TBL] [Abstract][Full Text] [Related]
9. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
Loos WJ; de Wit R; Freedman SJ; Van Dyck K; Gambale JJ; Li S; Murphy GM; van Noort C; de Bruijn P; Verweij J
Cancer Chemother Pharmacol; 2007 Feb; 59(3):407-12. PubMed ID: 17051369
[TBL] [Abstract][Full Text] [Related]
10. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe.
Majumdar AK; McCrea JB; Panebianco DL; Hesney M; Dru J; Constanzer M; Goldberg MR; Murphy G; Gottesdiener KM; Lines CR; Petty KJ; Blum RA
Clin Pharmacol Ther; 2003 Aug; 74(2):150-6. PubMed ID: 12891225
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial.
Xiong J; Zhao G; Yang S; Chen J
Adv Ther; 2019 Feb; 36(2):355-364. PubMed ID: 30607545
[TBL] [Abstract][Full Text] [Related]
12. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
13. Antiemetic efficacy of combined aprepitant and dexamethasone in patients at high-risk of postoperative nausea and vomiting from epidural fentanyl analgesia.
Kawano H; Matsumoto T; Hamaguchi E; Manabe S; Nakagawa M; Yamada A; Fujimoto M; Tada F
Minerva Anestesiol; 2015 Apr; 81(4):362-8. PubMed ID: 25220550
[TBL] [Abstract][Full Text] [Related]
14. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Longo F; Mansueto G; Lapadula V; De Sanctis R; Quadrini S; Grande R; Gori B; Altavilla A; D'Antoni I; Del Signore E; Stumbo L; De Luca C; Cimadon B; Cortesi E; Gamucci T; Di Seri M
Support Care Cancer; 2011 Aug; 19(8):1159-64. PubMed ID: 20552375
[TBL] [Abstract][Full Text] [Related]
15. Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis.
Burns D; Kula J; Marshall S; Ashworth E; Ornelas M
Adv Ther; 2020 Jul; 37(7):3265-3277. PubMed ID: 32447650
[TBL] [Abstract][Full Text] [Related]
16. Phase III Randomized Trial of Palonosetron and Dexamethasone With or Without Aprepitant to Prevent Nausea and Vomiting Induced by Full-dose Single-day Cisplatin-based Chemotherapy in Lung Cancer.
Wu F; Lin X; Yang Z; Sun Z; Zeng F; Heng J; Qu J; Zeng L; Yang N; Zhang Y
Clin Lung Cancer; 2018 Nov; 19(6):e913-e918. PubMed ID: 30197265
[TBL] [Abstract][Full Text] [Related]
17. Effect of Aprepitant on Etoposide Pharmacokinetics in Patients with Testicular Cancer: A Pharmacokinetic Study to Determine the Absence of a Clinically Relevant Interaction.
Strik J; de Jong LAW; Sijm J; Desar IME; van Erp NP
Clin Pharmacol Ther; 2024 Jan; 115(1):135-138. PubMed ID: 37867292
[TBL] [Abstract][Full Text] [Related]
18. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
[TBL] [Abstract][Full Text] [Related]
19. Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.
Hsyu PH; Pignataro DS; Matschke K
Eur J Clin Pharmacol; 2017 Jan; 73(1):49-56. PubMed ID: 27718000
[TBL] [Abstract][Full Text] [Related]
20. Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy.
Hamada S; Hinotsu S; Kawai K; Yamada S; Narita S; Kamba T; Nishiyama H; Arai Y; Habuchi T; Ogawa O; Kawakami K
Support Care Cancer; 2014 Aug; 22(8):2161-6. PubMed ID: 24652048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
